StemCell Therapy

DUBLIN--(BUSINESS WIRE)--The "Global Wave-front Aberrometer Market: Growth, Trends and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

The global wave-front aberrometer market is expected to exhibit a healthy CAGR over the forecast period, due to the growing burden of eye diseases and technological advancements in the devices.

According to the World Health Organization, around 1 billion people in 2019 suffered from blindness because of unaddressed refractive errors, near vision impairment and presbyopia globally. Uncorrected refractive errors are one of the major reasons for blindness. Hence, this emerges the need for novel diagnostic tools which is expected to increase the demand for wave-front aberrometer.

Key Market Trends

Myopia Segment Expected to Hold a Significant Market Share

Myopia segment is expected to show significant growth in the wave-front aberrometer market due to the higher prevalence of myopia. According to the American Optometric Association, in 2018, approximately 30% of people were living with the problem of near-sightedness in the United States. Furthermore, according to the study of the Journal of Clinical Ophthalmology, in 2016, when a LASIK surgery was performed with the help of high-resolution aberrometer in a myopic patient, the outcomes of it was found to be quite effective.

Also, advancements in products related to wave-front aberrometer are expected to be major contributors to market growth. For instance, in 2018, Oculus, Barrett Toric Calculator and Olsen ray-tracing formula to Pentacam AXL. These new features help in taking the data of the posterior and anterior corneal surface and thickness. Hence, these factors are expected to impact positively on the wave-front aberrometer market in this segment.

North America Expected to Hold a Significant Share

North America expected to hold a major market share in the global wave-front aberrometer market due to the higher prevalence of eye-related diseases and increasing aging population. According to the National Institute of Health, currently over millions of people in the United States are affected by one or the other eye condition and the aging population is at greater risk. Furthermore, according to the Centre for Disease Control and Prevention, in 2017, around 8 million people in the United States were diagnosed with vision impairment because of refractive error. Hence, this factor is expected to increase the demand for wave-front aberrometer.

Competitive Landscape

Companies are taking initiatives such as launching new products to grow their presence in the market. For instance, in 2018, Essilor introduced a new product in the market, WAM700+ wave-front aberrometer. It is based upon Shack-Hartmann wavefront technology and fully-automated instrument. Some of the companies which are currently dominating the market are Novartis AG (Alcon), Carl Zeiss, Luneau Technology, Tracey Technologies, Essilor, Nidek Inc., Johnson & Johnson Visioncare Inc., SCHWIND eye-tech-solutions, Optikon and Marco.

Key Topics Covered

1 INTRODUCTION

1.1 Study Assumptions

1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Growing Burden of Eye Disease

4.2.2 Technological Advancements in Product

4.3 Market Restraints

4.3.1 Lack of Skilled Personnels

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Application

5.1.1 Hyperopia

5.1.2 Myopia

5.1.3 Astigmatism

5.1.4 Others

5.2 Geography

5.2.1 North America

5.2.2 Europe

5.2.3 Asia-Pacific

5.2.4 Rest of the World

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Alcon

6.1.2 Carl Zeiss

6.1.3 Essilor

6.1.4 Johnson & Johnson Visioncare Inc.

6.1.5 Luneau Technology

6.1.6 Marco

6.1.7 Nidek Inc.

6.1.8 Optikon

6.1.9 SCHWIND eye-tech-solutions

6.1.10 Tracey Technologies

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/tpiye2

Read the original here:
Global Wave-front Aberrometer Market: Growth, Trends and Forecast (2020-2025) Featuring Alcon, Carl Zeiss, Essilor, and Johnson & Johnson...

X Ambassadors have always championed the visually impaired community, and on Thursday (August 20), brothers Casey and Sam Harris are partnering with Foundation Fighting Blindness and Two Blind Brothers for a benefit livestream to raise money for research dedicated to curing blindness.

Music to Our Eyes is set to take place at 7pm EST / 4pm PST on August 20 and will feature an acoustic performance from Casey and Sam that includes their hits Renegade, Unsteady, Hold You Down, and more, along with an interview. The event is free; however, those who are able to contribute a donation are encouraged to do so.

This partnership is particularly special to the brothers. Casey was born with with a rare genetic disease called Senior-Loken syndrome that affects the kidneys and retinas. As a result, he was born legally blind.

We are so excited and honored to be collaborating with Two Blind Brothers for this livestream conversation and acoustic performance with Sam and Casey Harris of X Ambassadors, Foundation COO Jason Menzo said in a statement. Together, we have this natural connection and unwavering commitment to providing hope and empowerment for the blind and visually impaired community.

Register to reserve your spot here.

Photo: Getty Images

More here:
X Ambassadors Team Up With Foundation Fighting Blindness For Livestream - iHeartRadio

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Intraocular Lens market.

Trusted Business Insights presents an updated and Latest Study on Intraocular Lens Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Intraocular Lens market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Intraocular Lens (IOL) Market Size, Share & Industry Analysis, By Type (Monofocal Intraocular Lens and Premium Intraocular Lens (Multifocal Intraocular Lens, Toric Intraocular Lens, and Others)), By Material (Polymethylmethacrylate (PMMA) and Foldable (Hydrophobic Acrylic, and Silicone & Collamer)), By End User (Hospitals & Ambulatory Surgery Centres, and Academic & Research Institutes) and Regional Forecast, 2020-2029 (Includes COVID-19 Business Impact)

The global Intraocular Lens (IOL) market size was USD 3,159.3 million in 2018 and is projected to reach USD 5,318.8 million by 2026, exhibiting a CAGR of 6.8% during the forecast period.

We have updated Intraocular Lens Market with respect to COVID-19 Impact.Inquire before buying

Cataract is one of the leading causes of blindness. Cataract removal is estimated to be the most common ophthalmic surgery across the globe. The intraocular lens is an artificial lens that is implanted in the eye during cataract procedures. Owing to strong government support and favorable reimbursement, more and more patients are undergoing cataract surgery. This has surged the adoption of an intraocular cataract lens. Initiatives to decrease the prevalence of cataract and an increasing number of NGOs providing free eye examinations and surgery are positively impacting the market.

The huge demand for the intraocular cataract lens has triggered the manufacturers to conduct research and development activities to provide advanced lenses that would help the patients with both near and distant vision. Many players are now focused on providing the trifocal, toric lens, and aspheric lenses that eliminate the need for wearing spectacles. For example, in December 2019, Johnson & Johnson Vision announced the U.S. launch of Tecnis Toric II, an intraocular cataract lens for correction of astigmatism in cataract patients. Furthermore, with the introduction of femtosecond laser-assisted cataract surgery, the demand for IOL is projected to increase by many folds.

MARKET DRIVERS

Increasing Number of Cataract Surgeries to Surge Demand for IOLCataract surgery is one of the most common ophthalmic procedures across the world. The rising prevalence of cataract and blindness associated with cataract has resulted in increasing the volume of cataract surgeries that are performed around the world. According to Eurostat, 4.5 million cataract procedures were performed in the European Union (EU) member states in 2016. This rising number of cataract procedures is anticipated to drive the IOL market revenue during the forecast period.

Furthermore, the rising prevalence of blindness and cataract is also one of the major reasons contributing to the expansion of the market. According to WHO, cataract is responsible for 47% of the world blindness and this is expected to favor the IOL market growth during the forecast period.

Launch of Several Government Initiatives for Cataract Elimination to Boost Market

The rising prevalence of cataract possesses an economic and health burden in many countries. This has resulted in the launch of various initiatives by the government for the elimination of cataracts. Vision 2020 is one such global initiative launched by the International Agency for the Prevention of Blindness (IAPB), with the aim to eliminate the main causes of avoidable blindness from the world. In addition, there is active participation by the government to achieve the target of Vision 2020 through reimbursement, eye checkup camps, and others. This is anticipated to accelerate the intraocular lens market growth in the forthcoming years.

SEGMENTATION

By Type Analysis

Monofocal Intraocular Lens Segment to Dominate Backed by Cost-effective NatureOn the basis of type, the market can be segmented into monofocal intraocular lens and premium intraocular lens. The premium intraocular lens segment is further classified into a multifocal intraocular lens, toric intraocular lens, and others. Monofocal intraocular lens segment is anticipated to dominate the IOL market share throughout the forecast period. Low pricing of monofocal lens compared to premium ones and favorable government reimbursement policies are the major factors attributable to the dominant share of monofocal IOLs.

On the other hand, premium IOLs have less penetration than monofocal IOLs. Also, many government-aided insurance policies do not cover the cost of premium IOLs and hence, the patient has to pay from their own pockets. Moreover, the advantages of the premium lenses over monofocal and the increasing preference for toric lenses are anticipated to drive the premium intraocular lens segment.

By Material Analysis

Foldable Segment to Witness a Remarkable Growth Owing to High Demand for Hydrophobic AcrylicBased on material, the market can be segmented into polymethylmethacrylate (PMMA) and foldable. The foldable segment is further divided into hydrophobic acrylic, hydrophilic acrylic, and silicone & collamer. The foldable segment is estimated to acquire a major portion of the market, primarily owing to its high refractive index and low water content, which is propelling its preference. Moreover, as intraocular cataract lenses are made from foldable material, they can be inserted through small incisions and are more widely used in cataract surgery. This intraocular lens market trend is anticipated to favor the growth of the foldable segment during the forecast period.Polymethylmethacrylate (PMMA) was the first material used for making the intraocular lens. Intraocular cataract lenses made from PMMA are significantly used in Europe and the rest of the world. This, coupled with the rising prevalence of cataract, is likely to favor the expansion of the polymethylmethacrylate (PMMA) segment during the forecast period.

By End User Analysis

Availability of Free Cataract Surgery to Drive the Growth of Hospitals & ASCs SegmentOn the basis of the end user, the market is segmented into hospitals & ambulatory surgery centers (ASCs), specialty clinics, and academic and research institutes. In terms of revenue, hospitals & ambulatory surgery centers segment accounted for the maximum portion of the market in 2018. An increase in the number of government hospitals and NGOs providing free of cost cataract surgeries, favorable health reimbursement, and increasing demand for daycare surgeries in hospitals are some of the major IOL market trends that are responsible for the growth of the segment.An increasing number of ophthalmic surgeons, a rising number of standalone eye clinics, and a significant increase in the number of cataract surgery in outpatient settings are expected to augment the expansion of the specialty clinics segment. Unite for Sight is an organization that provides financial and human resources to eye clinics around the globe. The increasing presence of such organizations to support eye clinics is also expected to boost the growth of this segment. The academic and research institutes segment is likely to propel owing to the active government efforts to train the ophthalmologists and an increasing number of doctors opting for fellowship programs to learn about the latest medical technologies.

REGIONAL ANALYSIS

North America generated a revenue of USD 892.9 million in 2018 and is projected to dominate the market throughout the forecast period. Technological advancement, such as custom cataract lens & Extended Depth of Focus (EDoF), and new product launches are the main reasons for the dominant North America IOL market share. According to the America Academy of Ophthalmology, 50 million people are projected to have a cataract in the U.S. by 2050. This is expected to favor the demand for an intraocular cataract lens in the U.S. during the forecast period.North America Intraocular Lens (IOL) Market Size, 2018

In Europe, the IOL market is anticipated to expand, owing to the increasing number of cataract surgery, rising adoption of femtosecond lasers for cataract surgery, and increased preference for toric lenses. According to Eurostat, in Germany, Italy, and Spain, the number of cataract surgeries performed per 1,000 populations in 2016 were 10, 9, and 7 respectively. This, coupled with the presence of various manufacturers in Europe, is expected to contribute to the growing demand for an intraocular cataract lens.

In Asia Pacific, the market is estimated to flourish owing to the rising prevalence of diabetes and cataract. Furthermore, increasing the volume of cataract surgery and strong government support are projected to boost the market for intraocular cataract lens. According to the National Programme for Control of Blindness and Visual Impairment (NPCB&VI), over 6.4 million surgeries were performed in India during 2016-2017. Such a high volume of cataract operations in India, China, and Japan are expected to augment the IOL market size in Asia Pacific. Increasing governmental efforts to improve the cataract surgical rate (CSR), rising number of ophthalmologists and rapid adoption of teleophthalmology are estimated to expand the intraocular lens market share in Latin America and the Middle East and Africa.

INDUSTRY KEY PLAYERS

Alcon and Johnson & Johnson Services, Inc. to Emerge as Leading PlayersIn terms of intraocular lens market revenue, Alcon and Johnson & Johnson Services, Inc. accounted for a leading position. Alcon had the highest IOL market share owing to the high demand and preference for AcrySof IOL. Increased efforts of the company to increase the penetration of premium lenses is the major reason for driving the growth of the company. The market shares of Johnson and Johnson Services, Inc. had increased drastically owing to the acquisition of Abbott Medical Optics in February 2017. Apart from this, increasing sales of the companys IOLs is anticipated to strengthen its position.

List Of Key Companies Profiled:

REPORT COVERAGE

Cataract is regarded as the leading cause of blindness in the world. Many programs are initiated to decrease the burden of cataract. This has resulted in increasing the number of cataract procedures and which, in turn, has surged the demand for an intraocular cataract lens. Furthermore, technological advancements, such as trifocal IOLs, accommodating IOLs, and others are expected to boost the adoption of IOL in the coming years. The report provides qualitative and quantitative insights on the global intraocular lens market trends and detailed analysis of market size & growth rate for all possible segments in the market.

An Infographic Representation of Intraocular Lens Market

View Full Infographic

To get information on various segments, share your queries with us

The report provides a detailed analysis of the market and focuses on key aspects such as leading companies, competitive landscape, and product types. Besides, the report offers insights into the market trends and highlights key industry developments, such as mergers, acquisitions, and partnerships. In addition to the aforementioned factors, the report encompasses several key insights, such as the number of cataract surgery for key countries, prevalence of cataract for key countries, regulatory scenario for key countries, reimbursement scenario for key countries, new product launches, an overview of government cataract initiatives, etc.

Report Scope & Segmentation

Segmentation

By Type

By Material

By End User

By Geography

INDUSTRY DEVELOPMENT:

December 2019: Johnson & Johnson Vision announced the U.S. launch of Tecnis Toric II, an intraocular lens for the correction of astigmatism in cataract patients.

August 2019: Alcon announced the launch of AcrySof IQ PanOptix Trifocal Intraocular Lens in the U.S. The product is designed to deliver near and distance vision without the requirement of glasses.

February 2017: Johnson & Johnson Vision completed the acquisition of Abbott Medical Optics, which strengthened the companys position in the ophthalmic devices market.

Looking for more? Check out our repository for all available reports on Intraocular Lens in related sectors.

Quick Read Table of Contents of this Report @ Intraocular Lens (IOL) Market Size, Share & Industry Analysis, By Type (Monofocal Intraocular Lens and Premium Intraocular Lens (Multifocal Intraocular Lens, Toric Intraocular Lens, and Others)), By Material (Polymethylmethacrylate (PMMA) and Foldable (Hydrophobic Acrylic, and Silicone & Collamer)), By End User (Hospitals & Ambulatory Surgery Centres, and Academic & Research Institutes) and Regional Forecast, 2020-2029 (Includes COVID-19 Business Impact)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read the original post:
Global Intraocular Lens (IOL) market size was USD 3159.3 million in 2018 and is projected to reach USD 5318.8 million by 2026, exhibiting a CAGR of...

August 25, 2020 -A newIRONSCALESreportfound a drastic increase in successful credential theft attempts sent through spoofed login pages and social engineering attacksduring the first half of 2020. And themost common recipients targeted with these attacks were those in the healthcare sector.

Researchers identified and analyzed fake login pages sent during the first half of the year, which are commonly used in support of spear-phishing campaigns and other hacks. Intotal, they identified more than 50,000 fake login pages, which spoofed login pages from over 200 prominent global brands.

Outside of healthcare, other leading recipients were those in financial services, government agencies, and technology industries.

The growing cyber threat of fake login pages [are] nefarious, yet often highly realistic looking pages [and] now a common tactic deployedby attackers seeking to obtain a persons login credentials to a legitimate website, such as a bank, email client, or social media site, among many other popular services, researchers explained.

The operation, commonly known as credential theft, is simple: target unsuspecting recipients with an email spoofing a trusted brand and persuade them via social engineering to insert their legitimate credentials, such asa username and password, into a fake login page either embedded within the body of an email or built into a phishing website, they added.

Once the victim has inputted their credentials, the hacker harvests the data to loginto real accounts and commence further illegal activities.

Just thisweek, the FBI and the Department of Homeland Security warned hackers were using voice phishing, or vishing, campaigns to build trust with victims, later duping them into logging intomaliciouswebsites made to appear astheir employers webpages.

Previous campaigns have spoofedZoom,Google,and MicrosoftOffice 365executive accounts, among others.

The IRONSCALES report found the top five brands with the most fake login pages are nearly identical to those that frequently have the most active phishing websites.

PayPal was the leading brand with 11,000 fake login pages, or 22 percent, closely followed by Microsoft with 9,500, or 19 percent and Facebook with 7,500, or 15 percent.eBaywas listed in fourth with 3,000pages, or 6 percent, with Amazon in last, with 1,500 pages, or 3 percent.

Other top brands with spoofed login pages included Aetna, Wells Fargo, Adobe, Apple, Tesco, and JP Morgan Chase, along with a host of others.

Although PayPal sits atop the list, the greatest risk may derive from the 9,500 Microsoft spoofs, as malicious Office 365, SharePoint and One Drive login pages put not just people but entire businesses a risk, researchers warned.

The researchers said its believed fake login pages are successful for two reasons. To start,malicious phishing emails containing spoofed logins often bypass technical controls like secure email gateways andSPAM filters, without requiring much investment in time, funds, or resources by the hacker.

Secondly, the attack's success may be due towhat is known as inattentional blindness or when an individual does not perceive the unexpected change hiding in plain sight.

Inattentional blindness became an internet sensation in 2012 when a video posted asking viewers how many white shirted players passed a ball. Intently focused on the task at hand, more than 50 percent of the viewers failed to recognize a woman in a gorilla suit in the middle of the picture, researchers wrote. Even people with phishing awareness training are susceptible to inattentional blindness.

Notably, about 5 percent of these attacks leveraging fake login pages were polymorphic in nature, where a hacker implements light but significant and often random change to an emails artifacts, such as its content, copy, subject line, sender name or template in conjunction with or after an initial attack has deployed.

An earlier IRONSCALES report showed 42percentof phishing attacks are polymorphic.The technique allows for the quick development of phishing attacks able to dupe signature-based email security tools that arent designed to recognize the modifications. As a result, a targeted victim could receive different versions of the same attack in their email account without being detected.

About 24 percent of the attacks spoofing Microsoft were polymorphic, with 314 permutations, followed by Facebook with 13 percent of permutation attacks or 160 permutations in total.

While we cannot say for certain why these brands have more permutations than others, we can make an educated guess that this occurred for one of two reasons:The security teams associated with these brands are actively looking to take down fake login pages, so attackers are forced to more frequently evolve the attack ever so slightly so to defeat human and technical controls, researchers mused.

These brands are a priority and or easy target for a certain hacking group(s), so there is more activity and therefore a need to constantly evolve in order to stay one step ahead of security teams, they added.

Microsoft has previously shared spear-phishing insights, which may help healthcare organizations better understand how these attacks work and mitigation techniques to harden enterprisedefenses.

Original post:
Credential Theft Via Spoofed Login Pages Increase, Healthcare Top Target - HealthITSecurity.com

Inherited retinal diseases marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to an annual growth rate of 4.40% in the above-mentioned forecast period.

The major players covered in the inherited retinal diseases market report are American Society of Gene & Cell Therapy, Spark Therapeutics, Inc., Invitae Corporation., The Choroideremia Research Foundation Inc, American Council of the Blind, Foundation Fighting Blindness, Guide Dogs for the Blind, Inc., Fighting Blindness, FIGHTING BLINDNESS CANADA, Lighthouse Guild, The RDH12 Fund For Sight, Sofia Sees Hope, Retina International, Usher Syndrome Coalition, VisionServe Alliance among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Ask For Complimentary Sample PDF| Request Athttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-inherited-retinal-diseases-market

How does this market Insights help?

Europe is assumed to be the most lucrative inherited retinal disease market due to a relatively bigger prevalence of acquired retinal complications copulated with a higher treatment-seeking rate.

Global Inherited Retinal Diseases Market Scope and Market Size

Inherited retinal diseases market is segmented on the basis of type, treatment type and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on type, inherited retinal diseases market is segmented into leber congenital amaurosis (LCA), retinitis pigmentosa, choroideremia, stargardts disease, and achromatopsia.

Inherited retinal diseases market has also been segmented based on treatment type such as gene therapy treatment, and symptomatic treatment.On the basis of distribution channel, the inherited retinal diseases market is segmented into hospital pharmacies, and retail pharmacies.

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-inherited-retinal-diseases-market

Global Inherited Retinal Diseases Market Drivers:

he growing awareness amongst the physicians and patients regarding the benefits associated with the usage of inherited retinal diseases has been directly impacting the growth of inherited retinal diseases market.

The swelling prevalence of the acquired retinal disorders is foreseen to push the growth of inherited retinal diseases treatment market. Expanding knowledge and treatment-seeking flow is anticipated to feed the germination of the inherited retinal diseases therapy business. Emphasizing knowledge of the inherited retinal disease surgery options and analysis of the condition is moreover awaited to magnify the growth of the inherited retinal disease surgery market.

The production businesses in the inherited retinal diseases market is moreover concentrating on the gene mutation-specific way for developing innovative outputs which is anticipated to accelerate the growth of inherited retinal diseases market. Numerous companies are contracting in collaborations, businesses to perform clinical experiments to promote acquired retinal disorder medication alternatives more efficiently. These certain mentioned factors are expected to drive the market growth in the forecasted period of 2020 to 2027.

To know more about the study,https://www.databridgemarketresearch.com/reports/global-inherited-retinal-diseases-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:[emailprotected]

See the article here:
Global Inherited Retinal Diseases Market Will Generate Massive Revenue in Coming Years| Top Leaders-Fighting Blindness, FIGHTING BLINDNESS CANADA,...

Meritocracy is the belief that holding power or success should be judged on peoples individual ability, rather than on wealth or social connections. At first glance, this appears to be a reasonable proposition. But the focus on individual merit becomes harder to fathom as one enters the messy world of structural inequality and discrimination.

As our research shows, ideologies of meritocracy and individualism create obstacles for collective action towards a more equal and just society. Our findings were published in the book Race in Education, the outcome of a thinktank on the effects of race at the Stellenbosch Institute for Advanced Study.

Using a methodology called Dreaming Workshops, our study explored how Grade 11 students, of around 16 and 17 years old, from different schools in the South African coastal city of Durban imagined race, racism and non-racialism in a utopian future.

Young South Africans are being socialised into a highly racialised society and experience severe disparities. Expecting them to eradicate racism without dismantling material inequalities is a deferral of adult responsibility. Mindful of this, we designed a study to listen to young peoples ideas, as opposed to looking to them for solutions.

The five schools that participated in this study, three government and two private, are located in a middle-class, formerly white area in Durban. The schools have, on average, a diverse but mostly middle-class student body, with some students travelling from townships to attend class. Under apartheid townships were poorly resourced and under-serviced residential spaces designated for people racialised as black. Each school in the study had approximately 20 students per class. One school markets itself as girls-only, one as boys-only, the other three are open to all genders.

Young people involved in the study were deeply aware of inequality. For them, reducing inequality was a priority if the country was to move towards a better future.

It is notable that non-racialism was not a concept volunteered by any of the students as a future ideal, despite it being a constitutional principle in South Africa. At present there is little clarity on the meaning of non-racialism. It is equated to a multiplicity of ideas, among them mobilisation against apartheid, multiracialism, multiculturalism, nation-building, and race-blindness.

What students did want eradicated from their utopia was racial discrimination and racism. The meanings they attached to race shifted depending on the conversation, for example, race when it related to racial quotas as opposed to race when it related to culture, identity or politics.

Racial identities played an important role in these young peoples sense of self. But some thought it is the weirdest thing ever that people sit in race groups during lunch breaks. They make sense of this by explaining that people sit with others who share their culture. Using race and culture as proxies for each other is very much part of the South African experience of racialisation.

The commitment to racial identities, however, was more complex than it first appeared. There was an uneasiness between accepting and feeling pride in racial identities, and not wanting them to count as measures of social value. They frequently vocalised a rejection of racial stereotypes and racism.

In each school, there were students committed to eradicating their own racist thoughts, who openly challenge parents and family members about racism and actively refused to essentialise their peers. Students felt a generational responsibility to challenge racial stereotypes.

They were also vehemently against race as a category in government policies. Arguments against racial quotas, such as broad-based black economic empowerment and affirmative action (race-based legislation aimed to redress past and current discriminations) were present in all the schools. As were statements that we need to get over blaming the past, or linking poverty with laziness, or refusing to recognise the role of privilege in individual achievement.

These sentiments reflected a socialisation process happening at schools, and in the family, that raised real tensions for young people. Many students were taught to believe that individual hard work pays dividends. Principles of individual success and meritocracy were well established in their homes, and valorised daily at their schools. Schools acutely focused on individual competition in sports and academic achievements, rewarding individual rather than collective effort.

The wiping out of the individual in favour of a group racial identity for employment and university entry appeared unfair and contradictory to the meritocratic values they were being taught to aspire to.

Read more: We need to unpack the word 'race' and find new language

These views were present in students who would be racialised as belonging to all four of South Africas racial categories, socially constructed in this country as black, Indian, Coloured and white.

Meritocratic arguments were also against the redistribution of wealth in South Africa. Taxing the rich was often seen as making the poor lazy. Here, class privilege was indiscernible from what would usually be thought of as a defence of white privilege.

In our view meritocratic sentiments are highly problematic in the context of structural inequality. In South Africa there is no equal playing field on which to justify individual merit.

It is not just race-blindness that we should guard against in South Africa; class-blindness too leads to a repetition of the status quo. Since structural inequalities fundamentally enable reproductions of racism this creates a complex dilemma for these students.

What does it mean to desire social justice and equality but refuse to give up any privileges?

This dilemma poses a challenge for education in South Africa. Certainly more frank and critical classroom conversations on race, class and culture are needed. More pressing is how to restructure schooling so that it is less focused on individual merit and reward.

This article is part of a series. Other authors include Barney Pityana, Gran Therborn, Nina Jablonski, George Chaplin and Njabulo Ndebele.

The three edited volumes of essays published by African Sun Media in 2018 (The Effects of Race, edited by Nina G. Jablonski and Gerhard Mar), 2019 (Race in Education, edited by Gerhard Mar), and 2020 (Persistence of Race, edited by Nina G. Jablonski) contain the complete representation of the projects scholarship.

Originally posted here:
What young people have to say about race and inequality in South Africa - The Conversation CA

More News27 Aug 2020 | 12:04 AM

New Delhi, Aug 26 (UNI) Border Security Force (BSF) on Wednesday apprehended seven Bangladeshi nationals who entered into Indian territory with the help of human traffickers near Mahendra Border Out Post (BoP) in Nadia district of West Bengal.

New Delhi, Aug 26 (UNI) With the national capital recoding more fresh infections compared to the recoveries, the recovery rate in the capital has witnessed a decline and went down under 90 per cent on Wednesday.

(Rptg, correcting Lead Para, Line 2)New Delhi, Aug 26 (UNI) To establish a transparent and comprehensive 'Performance Rating' System for its Consultants, Contractors and Concessionaires, the NHAI has developed a 'Vendor Performance Evaluation System'.

New Delhi, Aug 26 (UNI) A shocking incident came into picture on Wednesday wherein two brothers allegedly committed suicide together by hanging themselves at old Delhi's famous Chandni Chowk area as a result of financial crisis.

New Delhi, Aug 26 (UNI) To establish a transparent and comprehensive 'Performance Rating' System for its Consultants, Contractors and Concessionaires, the NHAI on Wednesday developed a 'Vendor Performance Evaluation System'.

Visit link:
Pranab Mukherjee's renal parameters slightly deranged, continues on ventilator - United News of India

ATLANTA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary received an add-on status for the pricing and reimbursement approval for ILUVIEN in the Netherlands from the Ministry of Health, effective September 1, 2020. Pricing and reimbursement approval was sought and secured by Alimeras distribution partner in France and the Benelux region, Horus Pharma S.A.S. (Horus). Horus is in the process of reviewing launch plans.

We are extremely pleased to have received this national coverage decision for ILUVIENs diabetic macular edema and non-infectious posterior uveitis indications in the Netherlands at the same time, said Rick Eiswirth, President and Chief Executive Officer of Alimera. Given Horuss impressive performance on the launch of ILUVIEN in France, we look forward to expanding distribution and sales in the Benelux region, and continuing to execute on our international growth strategy.

ILUVIEN is a sustained release intravitreal implant indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapiesand for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU).

We are genuinely pleased that for the second time, our collaboration with Alimera Sciences regarding ILUVIEN in Europe, has been fruitful, said Maja Lausevic, Chief Operating Officer, Horus Pharma. Access to ILUVIEN therapy is widely anticipated by ophthalmologists and patients in the Netherlands, and we are enthusiastic to provide this unique therapeutic solution to them and look forward to the official launch.

About ILUVIEN

http://www.ILUVIEN.com

The Companys primary product is ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING technology, ILUVIEN is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce the recurrence of disease, enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. In March 2019, ILUVIEN received approval in the 17 countries under the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The 17 European countries include the U.K., Germany, France, Italy, Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway, Finland, Sweden, Poland, Czechia, the Netherlands, and Luxembourg. The non-infectious posterior uveitis indication for ILUVIEN was launched in Germany and the U.K. in 3Q 2019. ILUVIEN is not approved for treatment of uveitis in the United States.

About Diabetic Macular Edema (DME)

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.

About Non-Infectious Posterior Uveitis(NIPU)

Posterior segment non-infectious uveitis is a chronic, inflammatory disease affecting the posterior segment of the eye, often involving the retina, and is a leading cause of blindness in developed and developing countries. It affects people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness. Patients with NIPU are typically treated with systemic steroids, which are effective, but over time frequently lead to serious side effects, ranging from acne, weight gain, sleep and mood disorders to hypertension and osteoporosis that can limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immune suppressants or biologics, which also can have severe side effects, including an increased risk of cancer and infection. As a result, there remains a significant need for new therapies with improved efficacy, tolerability, and safety profiles to manage this disease.

About Alimera Sciences, Inc.

http://www.alimerasciences.com

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit http://www.alimerasciences.com.

AboutHorus Pharma S.A.S.

Founded in 2003 in France, Horus Pharma is an independent European laboratory specialized in ophthalmology. It has been recognized to date as one of the main innovative European actors in corneal reconstruction treatments, particularly in the areas of dry eye, scarring and keratoconus. Focused on patient safety, Horus Pharma has developed recognized expertise in the development of preservative-free formulations and product delivery systems. For further details, please visit http://www.horus-pharma.com.

Forward Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimeras expectations with respect to access to ILUVIEN for patients in the Netherlands. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, Horus ability to launch ILUVIEN in the Netherlands for both uveitis and DME, the willingness of healthcare professionals and organizations in the Netherlands to adopt ILUVIEN for the two indications and Horuss ability to get pricing and reimbursement in the remaining Benelux countries, Belgium and Luxembourg, as well as other factors discussed in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of Alimeras Annual Report on Form 10-K for the year endedDecember 31, 2019 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, which are on file with theSecurities and Exchange Commission(SEC) and available on theSECswebsite atwww.sec.gov.

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Continue reading here:
Alimera Sciences Announces National Reimbursement Granted for ILUVIEN in the NetherlandsILUVIEN receives pricing and reimbursement approvals for both...

Cranial cruciate ligament rupture (CCLR) is a leading cause of pelvic limb lameness in dogs. About 6% of Labs suffer from this orthopedic problem and since this breed is one of the most popular in the U.S.,Michael Conzemius, DVM, PhD, DACVS, andMolly McCue, DVM, MS, PhD, DACVIM, with the University of MinnesotaCollege of Veterinary Medicinedecided to collaborate on a study to determine the diseases heritability in Labrador Retrievers and they wanted to measure the extent to which CCLR is associated with genetics in this breed.

Cruciate ligaments, connecting the femur to the tibia bones, are called cranial and caudal in quadrupeds, such a dogs; the cranial cruciate ligament (CCL) is analogous to the anterior cruciate ligament (ACL) in humans. These ligaments are prone to rupture, in humans, dogs, horses and, in other species.

Previous work has shown that approximately 2.5% of dogs are affected with at least one CCLR, and various factors including breed, sex, age and sterilization statusincluding age at sterilizationhave some effect on the likelihood of experiencing a CCLR(Witsberger et al. 2008; Simpson et al. 2019).

While this condition is mainly found in large and giant breeds of dogs, it has been noted that it has a low incident rate in Greyhoundsa large-sized breedso this has lead researchers to theorize that there is a genetic influence to the occurrence of CCLR.

Sign up for our newsletter and stay in the know.

The researchers explained that, interestingly, in most cases with dogs, CCLR isnt a contact injury or due to acute trauma. This has led to various causal theories: degenerative processes may be occurring within the ligament; there exists an inability to repair damaged tissue at a typical rate; or defects exist within the dogs general conformation (Buote et al. 2009; Muir et al. 2011).

The methodology of this study has proven effective in horses, and this was the first study to use these techniques to estimate heritability in dogs with CCLR. The scientists found relatively high heritability for CCLR in Labrador Retrievers, which indicates that genetics contribute substantially to the diseases prevalence in the breed.

These findings should help get clinicians one step closer to a genetic test for earlier diagnosis and treatment. However, heritability estimates do not pinpoint the genes involved, so the scientists say future studies should focus on determining which genetic mutations specifically increase the risk for CCLR in this breed.

As Michael Conzemius, the studys co-author noted, This is an extension of research that we began nearly 20 years ago in an effort to establish the role of genetics in this disease that is exceptionally common in some breeds of dogs. Our long-term goal has always been identifying mechanisms to decrease the frequency of cranial cruciate ligament disease. We plan to continue this work and hopefully it will contribute to a functional genetic test.

This research was funded by the National Institutes of Health (K01OD027051), Veterinary Orthopedic Society, Tata Group Endowment at the University of Minnesota, and the Bernice Barbour Foundation.

View original post here:
The Importance of Genetics in Leading Orthopedic Problem in Dogs - The Bark

Best listening experience is on Chrome, Firefox or Safari. Subscribe to Federal Drives daily audio interviews onApple PodcastsorPodcastOne.

A major breakthrough in treating a genetic disorder can be credited to our next guest. Sickle cell disease is a blood disorder that affects more than 20 million people worldwide. Theyve recently had a breakthrough. Federal News Networks Eric White spoke to one of the scientists at the National Institutes of Health conducting research on sickle cell on Federal Drive with Tom Temin. Dr. John Tisdale is a finalist in this years Service to America Medals program.

Dr. John Tisdale: I trained in internal medicine, and that was in the early 90s. I encountered patients with sickle cell disease who were experiencing extraordinary pain. And at that time, all we had was pain medication. So we would give pain medication and IV fluids because very often dehydration was what provoked the pain episode in these patients. But we had no specific treatments, nothing that were directed at the disease itself, only management of the pain. It was strange to me because I had learned about sickle cell disease in genetics classes and had known that we knew the basis for this disease longer than any other disease, yet we had no treatment, nothing. So it motivated me to think about ways that could treat the disease. The obvious thing that came to mind was a bone marrow transplant because we had a very active bone marrow transplant service at Vanderbilt. And I found that a very exciting way to approach disease and it just made sense that if you have a blood disease that causes all this difficulty in blood comes from the bone marrow well one obvious way to fix it is just to replace the bone marrow with one that doesnt have the genetics that causes the disease, like a brother or sister that we were doing for other kinds of diseases, and that could potentially cure the disease. And in fact, I learned that it had been done before in a patient who had leukemia. And that was a reason for her getting a bone marrow transplant. But she also had sickle cell disease and she was cured of both. There were some efforts during that time to bring that to the clinic, in the pediatric setting, and everything is always easier with kids because theyre tougher when it comes to medications and transplants and all the things that you can think of doing, chemotherapy. That got me motivated into studying hematology and bone marrow transplant, and trying to figure out ways to bring bone marrow transplant to patients with sickle cell disease.

Eric White: This sickle cell disease, obviously weve all heard of it. Even if you know what it is, its still a complicated disease. Can you explain what is the latest research says that sickle cell disease actually does over? As I said its a very strange disease that affects the body in many different ways. Are there any new findings as to how it does actually affect it?

Dr. John Tisdale: Well, I think weve known for a very long time exactly what happens in this disease. It arose as a way to protect from death from malaria. So just one little letter off for the gene that makes our hemoglobin, and hemoglobin is the molecule in red blood cells that carries oxygen around the blood. So one letter off in part of that molecule, and you have protection from malaria, you dont get the very severe form of malaria because the red cell is not as hospitable to the parasite. So that gets selected for in areas where theres malaria, like in Sub Saharan Africa. But if you get two copies of the gene, one from mom and one from dad, you get this disease, sickle cell disease because the hemoglobin now is different than the normal hemoglobin. Instead of carrying oxygen around and staying in solution like it does normally, you have a hemoglobin that once it does its job by dropping off oxygen out in the body, it can come out of solution and become like rock hard, distort the shape of the red cell thats normally squeezing through blood vessels to find its way back to the lungs to get more oxygen. When that happens, block the circulation. So it kind of causes a log jam and all the blood behind it gets stuck. And so wherever that happens, gets starved of its oxygen. So I mean, if it happens in the brain, for example, it causes a stroke. And so kids, eight years old can have a stroke that looks exactly like the sort that we see in the elderly who have vascular disease. If it happens in the muscle, its extremely painful or in the bone. And it happens in every organ in the body. And as a result can damage those organs over time and significantly shorten the lifespan of patients with sickle cell disease. So the lifespan currently is in the 40s. And thats much improved over the last several decades, but its still much lower than then people without the disease.

Eric White: So with your research, what has given you the most promise? What results have you all hung on to whether its bone marrow transplant or gene therapy? Is there one that you say hey, we might be on to something here?

Dr. John Tisdale: Well, I think the biggest breakthrough that weve made is figuring out just how much of the bone marrow we have to fix. So it turns out, we dont have to completely replace the bone marrow with somebody elses bone marrow to make the blood normal. So normally in a bone marrow transplant you you have to give chemotherapy to take away all of the cells that are making blood. Thats kind of like tilling the garden, right? You cant go out in the middle of a cornfield and spread a bunch of tomato seeds and expect to have tomatoes there, theyre not going to grow because the corns already growing. So the thinking is to do a bone marrow transplant, you have to harvest the corn, till the soil, plant the sees. And the same is true for bone marrow transplants. But it turns out for sickle cell disease, we dont have to do that. Weve had patients who even though we try to get rid of all their bone marrow, we failed and they had up to 80% of their own bone marrow still making blood, and presumably sickle blood. But if we had only 20% from the donor that was making normal blood, that would result in all of the blood being normal. And thats just because sickle cells live 10 or 12 days in the circulation, normal cells live 120 days in the circulation. And since the normal cells have such an advantage, you dont really have to completely eradicate the patients own bone marrow or you dont have to fix every cell. So thats important. That told us two things. One, we dont have to use toxic chemotherapy that we normally have to use to do a bone marrow transplant. And furthermore, we can start to think about gene therapy as an approach because we know we can never fix every cell. But if we could fix 20% of cells, we would predict from what weve observed in patients getting transplants from their brother or sister, that wed be able to fix the disease. And were well above the 20% mark when we transfer genes into cells. We can also correct the mutation at higher than 20%. So knowing that we only have to get to 20% has allowed us to start clinical trials, using the patients own bone marrow where we take those seeds out and try to fix them and give them back. If we can make 20%, we think we can fix the disease.

Eric White: Is there anything else that youd like to get the word out on? Is there any way people might be able to help or if if they have any family members who are suffering from this, if theres anything you would like to tell them?

Dr. John Tisdale: Well, I mean, I think the thing thats very important to understand for anyone with a genetic disease or otherwise is that clinical trials are the way that we make progress. And so participating in clinical trials is important for moving the field forward, and we partner with our patients and their family and their support structure to do these clinical trials and to make progress in the disease. So its extraordinarily important for people to understand that. Thats the way we make progress.

Read this article:
NIH scientists credited with breakthrough in treating a genetic disorder - Federal News Network

On the surface, the humble melon may just look like a tasty treat to most. But researchers from Japan have found that this fruit has hidden depths: retrotransposons (sometimes called "jumping sequences") may change how genes are expressed.

In a study published recently inCommunications Biology, researchers from the University of Tsukuba and the National Agriculture and Food Research Organization (NARO) have revealed that retrotransposons had a role in altering gene expression when melon genomes were diversifying, and may affect gene expression that induces fruit ripening.

Melons comprise one of the most economically important fruit crops globally. A special feature of melons is the coexistence of two fruit types: climacteric (which produce ethylene and exhibit a burst in cellular respiration as ripening begins), and non-climacteric. Ethylene is a plant hormone important to the regulation of climacteric fruit-ripening traits such as shelf life, which is of major economic importance.

"Because Harukei-3 melons produce ethylene during ripening, we wanted to look at ethylene-related gene expression in this type of melon," says lead author of the study Professor Hiroshi Ezura. "Harukei-3 produces an especially sweet fruit if grown in the right seasons. Because of its taste and attractive appearance, Harukei-3 has been used for a long time in Japan as a standard type for breeding high-grade muskmelon."

To examine ethylene-related gene expression, the researchers assembled the whole genome sequence of Harukei-3 by using third-generation nanopore sequencing paired with optical mapping and next-generation sequencing.

"We compared the genome of Harukei-3 with other melon genomes. Interestingly, we found that there are genome-wide presence/absence polymorphisms of retrotransposon-related sequences between melon accessions, and 160 (39%) were transcriptionally induced in post-harvest ripening fruit samples. They were also co-expressed with neighboring genes," explains Dr. Ryoichi Yano, senior author. "We also found that some retrotransposon-related sequences were transcribed when the plants were subjected to heat stress."

Retrotransposons are transposons (also referred to as "jumping sequences" because they can change their positions within a genome) with sequences similar to those of retroviruses.

"Our findings suggest that retrotransposons contributed to changes in gene expression patterns when melon genomes were diversifying. Retrotransposons may also affect gene expression that brings on fruit ripening," says Professor Ezura.

The Harukei-3 genome assembly, together with other data generated in this study, is available in the Melonet-DB database. Combined with future updates, this database will contribute to the functional genomic study of melons, especially reverse genetics using genome editing.

Reference: Yano et al. (2020).Comparative genomics of muskmelon reveals a potential role for retrotransposons in the modification of gene expression. Communications Biology.DOI: https://doi.org/10.1038/s42003-020-01172-0.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Genetic Study Reveals Theres More to Melons Than Meets the Eye - Technology Networks

Global CRISPR and Cas Genes Market Snapshot

CRISPR-Cas systems are efficient and easily programmable nucleic acid-targeting tools, with usage expanding beyond research and therapeutic development to precision breeding of plants and animals and engineering of industrial microbes. CRISPR-Cas systems have potential applications in microbial engineering including bacterial strain typing, immunization of cultures, autoimmunity or self-targeted cell killing, and the engineering or control of metabolic pathways for improved biochemical synthesis. The global CRISPR and Cas genes market was valued at US$ 1,451.6 Mn in 2017 and is anticipated to reach US$ 7,234.5 Mn by 2026, expanding at a CAGR of 20.1% from 2018 to 2026.

Read Report Overview - https://www.transparencymarketresearch.com/crispr-cas-genes-market.html

Usage of CRISPR-Cas systems in bacteria, rise in government spending on research and development of genome editing, increase in incidence of genetic disorders, and usage of CRISPR/Cas9 technology to improve crop production drive the global CRISPR and Cas genes market. Genome editing technologies such as CRISPR/Cas9 is a revolutionary step in the field of biomedical research. Application of CRISPR/Cas9 focusing on somatic cell genome editing program is aimed at accelerating the use of these technologies to treat various genetic disorders. However, ethical issues concerning CRISPR and lack of skilled professionals restrain the global CRISPR and Cas genes market.

The global CRISPR and Cas genes market has been segmented based on product type, application, end-user, and region. In terms of product type, the global market has been bifurcated into vector-based Cas and DNA-free Cas. Based on application, the global CRISPR and Cas genes market has been classified into genome engineering, disease models, functional genomics, knockout/activation, and others. In terms of end-user, the global market has been categorized into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations. Based on region, the global CRISPR and Cas genes market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26417

In terms of product type, the vector-based Cas segment dominated the global market in 2017, accounting for 62.1% share. Vector-based Cas expression systems are useful for researchers who focus on enriching Cas9-expressing cells or strive to establish a stable cell line. Vector-based Cas is also available with an inducible promoter that supports the creation of stable cell lines with minimal background expression, or for temporal control over Cas9 expression for wide-ranging experimental applications. The DNA-free Cas segment is anticipated to gain market share during the forecast period. Advantages such as gene editing with DNA-free CRISPR-Cas9 components to reduce potential off-targets and potential usage of CRISPR-Cas9 gene editing to find correlations with human diseases in model systems drive the segment.

Request for Analysis of COVID-19 Impact on CRISPR and Cas Genes Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=26417

Based on application, the genome engineering segment dominated the global CRISPR and Cas genes market in 2017. CRISPR technology allows genetic material to be added, removed, or altered at particular locations in the genome. Cas9 mRNA or purified Cas9 protein is the source for Cas9 nuclease expression in genome engineering experiments. Genomic engineering is the synthetic assembly of complete chromosomal DNA that is more or less derived from natural genomic sequences. Disease models was the second largest segment of the global market. CRISPR/Cas9 gene editing has also been applied in immunology-focused applications such as the targeting of C-C chemokine receptor type 5 and programmed death-1 gene. This technology has been increasingly applied in the study or treatment of human diseases, including Barth syndrome effects on the heart, Duchenne muscular dystrophy, hemophilia, -thalassemia, and cystic fibrosis.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=26417

In terms of end-user, the biotechnology & pharmaceutical companies segment dominated the global CRISPR and Cas Gene market in 2017. Adoption of CRISPR technology by pharmaceutical & biotechnology companies through strategic partnerships with innovators drives the segment. In 2017, CRISPR Therapeutics established a joint venture called Casebia Therapeutics LLP with Bayer HeathCare and its subsidiaries. Academic & government research institutes was the second largest segment of the global market.

Based on region, North America and Europe dominated the global CRISPR and Cas genes market in 2017, accounting for 71% share. Rise in research activities and technological advancements are expected to drive the CRISPR and Cas genes market in the regions during the forecast period. In 2016, a human clinical trial was initiated for the use of CRISPR to treat diseases in the U.S. Increase in adoption of technology and presence of key players in the region are likely to accelerate the growth of the CRISPR and Cas genes market in Europe during the forecast period.

Buy CRISPR and Cas Genes Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=26417&ltype=S

Major players operating in the global CRISPR and Cas genes market include Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc. These players adopt organic and in-organic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and capture market share.

Browse More Trending Reports by Transparency Market Research:

fNIRS Brain Imaging System Market

https://www.transparencymarketresearch.com/fnirs-brain-imaging-system-market.html

Healthcare ERP Market

https://www.transparencymarketresearch.com/healthcare-erp-market.html

Seborrheic Keratosis Treatment Market

https://www.transparencymarketresearch.com/seborrheic-keratosis-treatment-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

More:
CRISPR and Cas Genes Market: Rise in Incidence of Genetic Disorders and Increase in Applications of CRISPR and Cas Genes to Propel Market - BioSpace

Combined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions

RUTHERFORD, NJ and MAPLE GROVE, MN, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the Company) (Nasdaq: CGIX), and StemoniX, Inc., today announced the entry into a definitive merger agreement. Cancer Genetics is a leader in drug discovery and preclinical oncology and immuno-oncology services. StemoniX, a privatecompany, isa leader in developing high-throughput disease-specifichuman organoid platforms integrated withleading-edge data science technologies. Under the terms of the merger agreement, StemoniX will merge with a newly formed subsidiary of Cancer Genetics in an all-equity transaction. Upon shareholder approval, the combined company expects to remain listed on the Nasdaq Stock Market. StemoniX will retain its name and become a wholly-owned subsidiary of Cancer Genetics.

The transaction will position the combined company to harness the synergies between two critical modalities of drug discovery and development - advanced animal models and relevant human high-throughput organoid platforms. The resulting integration of scientific and technology-based expertise, skilled management teams, and ability to offer customers an end-to-end platform will de-risk and accelerate development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the combined company. In combination, Cancer Genetics and StemoniX currently enjoy partnerships and R&D relationships with dozens of global pharmaceutical and biotechnology companies.

"The process of discovering and developing a new drug candidate takes years and comes with a price tag of hundreds of millions - or even billions - of dollars. However, we are at unique time in the drug discovery industry as the convergence of technological innovations in both biology and software will transform conventional workflows in time and accuracy. To convert the time-consuming and labor-intensive process of developing a drug for market, we now look to supplement traditional discovery and drug approval mechanisms to include humanized cell-based assays with artificial intelligence (AI) along with our core vivoPharm business. Given that our strategy and approach are strongly aligned with those of StemoniX, we are pleased to have moved forward with this proposed transaction," stated Jay Roberts, Chief Executive Officer of Cancer Genetics.

The pharma industry and society are at a critical pivot point. Viral pandemics and diseases lacking treatments require a new way of innovation. The proposed merger expects to expand our ability to engage with a larger audience of potential partners and expand our internal capabilities as we deliver on our mission to rapidly discover the safest and most effective therapeutics on behalf of our partners and our shareholders. The mission will stay consistent - allow scientists to quickly and economically conduct high-throughput toxicity and drug development studies in ready-to-assay plates containing functional microOrgans, stated Ping Yeh, Chief Executive Officer of StemoniX.

ABOUT THE TRANSACTION

Pursuant to the merger agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of its common stock which will represent approximately 78% of the outstanding common stock of Cancer Genetics, subject to certain adjustments and prior to the effects of the financing referred to below, with the current equity holders of Cancer Genetics retaining 22% of the common stock immediately following the consummation of the merger.

The Boards of Directors of both companies have approved the proposed merger, which is expected to close in the fourth quarter of 2020, subject to the approval of the shareholders of both Cancer Genetics and StemoniX, financing and other customary closing conditions.

H.C. Wainwright & Co. is acting as financial advisors to the Board of Directors of Cancer Genetics, and Lowenstein Sandler is acting as its legal counsel. Northland Securities, Inc. is acting as financial advisor to the Board of Directors of StemoniX and Taft, Stettinius & Hollister is acting as its legal counsel.

ABOUT CANCER GENETICS

Through its vivoPharm subsidiary, Cancer Genetics offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers. The Company is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities. For more information, please visit http://www.cancergenetics.com.

ABOUT STEMONIX, INC.

StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPSC) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients. To learn more about how StemoniX products and services are accelerating discoveries, please visit http://www.StemoniX.com.

For more information, please visit or follow CGI at:

http://www.cancergenetics.com

Twitter: @Cancer_Genetics

And StemoniX at:

http://www.StemoniX.com

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.s expectations regarding satisfaction of closing conditions, consummation of the merger, future financial and/or operating results, and potential for our services, future revenues or growth in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our ability to satisfy all closing conditions to the merger, our attempts to adapt to the global coronavirus pandemic, achieve profitability by increasing sales of our pre-clinical services, maintain our existing customer base and avoid cancellation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs and conditions to the merger, properly evaluate strategic options, and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2019 and Form 10-Q for the quarter ended June 30, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Investor Contacts:Jennifer K. Zimmons. Ph.D.Investor RelationsZimmons International Communications, Inc.Email: jzimmons@zimmonsic.comPhone: +1.917.214.3514

More:
Cancer Genetics and StemoniX Sign Definitive Agreement to Merge - GlobeNewswire

A perfect mix of quantitative & qualitative Preimplantation Genetic Diagnostics (PGD)market information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Preimplantation Genetic Diagnostics (PGD) market. The study bridges the historical data from 2014 to 2019 and estimated until 2026.

The Preimplantation Genetic Diagnostics (PGD)Market report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus Catastrophe The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of Preimplantation Genetic Diagnostics (PGD)Industry.

Get Sample PDF along with few company profileshttps://inforgrowth.com/sample-request/6491084/preimplantation-genetic-diagnostics-pgd-market

The Top players are

Market Segmentation:

By Product Type:

On the basis of the end users/applications,

Get Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6491084/preimplantation-genetic-diagnostics-pgd-market

Be the first to knock the door showing the potential that Preimplantation Genetic Diagnostics (PGD)market is holding in it. Uncover the Gaps and Opportunities to derive the most relevant insights from our research document to gain market size.

A major chunk of this Global Preimplantation Genetic Diagnostics (PGD)Market research report is talking about some significant approaches for enhancing the performance of the companies. Marketing strategies and different channels have been listed here. Collectively, it gives more focus on changing rules, regulations, and policies of governments. It will help to both established and new startups of the market.

The study objectives of this report are:To analyze global Preimplantation Genetic Diagnostics (PGD)status, future forecast, growth opportunity, key market, and key players.To present the Preimplantation Genetic Diagnostics (PGD)development in the United States, Europe, and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market, and key regions.

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players List https://inforgrowth.com/discount/6491084/preimplantation-genetic-diagnostics-pgd-market

Major Points from Table of Contents

1 Preimplantation Genetic Diagnostics (PGD) Preimplantation Genetic Diagnostics (PGD) Market Overview2 Preimplantation Genetic Diagnostics (PGD) Market Competition by Manufacturers3 Production Capacity by Region4 Global Preimplantation Genetic Diagnostics (PGD) Market by Regions5 Production, Revenue, Price Trend by Type6 Global Preimplantation Genetic Diagnostics (PGD) Market Analysis by Application7 Company Profiles and Key Figures in Preimplantation Genetic Diagnostics (PGD) Business8 Preimplantation Genetic Diagnostics (PGD) Manufacturing Cost Analysis9 Marketing Channel, Distributors and Customers10 Market Dynamics11 Production and Supply Forecast12 Consumption and Demand Forecast13 Forecast by Type and by Application (2021-2026)14 Research Finding and Conclusion15 Methodology and Data Source.

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players List https://inforgrowth.com/discount/6491084/preimplantation-genetic-diagnostics-pgd-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Originally posted here:
COVID-19 Update: Global Preimplantation Genetic Diagnostics (PGD) Market is Expected to Grow at a Healthy CAGR with Top players: Illumina, Inc.,...

The Federal Circuit has issued a precedential decision in XY LLC v Trans Ova Genetics. Judge Stoll, joined by Judge Wallach and Senior Judge Plager, held that claims directed to a specific improvement to an otherwise-known process are patent eligible under 35 USC section 101. In reversing the district court, the court held that, although the invention applies mathematical equations to effect the claimed improvement, the claims were directed to a specific improvement that separates the invention from the prior art - not to an abstract idea.

The courts decision details several principles underlying the section 101 analysis and offers lessons for litigants addressing eligibility determinations.

XYs 559 patent involves flow cytometry technology for sorting non-human mammalian particles. This technology is particularly useful in animal breeding to guarantee the sex of offspring, allowing sperm cells to be sorted based on whether the cell carries an X or Y chromosome. While conventional flow cytometry technology made it difficult to discriminate between similar particles of different populations, the 559 patent claims an improvement that uses mathematical equations to reconfigure data corresponding to the particles, such as by rotating it, in order to increase spatial separation of data points and make it possible to discriminate between particles. XYs improved methods allow populations to be selected more accurately than in any other prior art system.

The district court decided the 559 patent claims were invalid under section 101. Starting with Alice step one, the court found the claims were directed to the abstract idea of a mathematical equation that permits rotating multi-dimensional data. It reasoned that, although the equation helps to discriminate between particles of different populations, the invention reduces down to applying a mathematical concept. Then, at Alice Step Two, the court held the asserted claims lack an inventive concept because it believed the claims offer nothing beyond the prior art.

Reversing the district court, the Federal Circuit decided on 31st July that the 559 patent claims are directed to a specific improvement to a flow cytometry method, not an abstract idea. Specifically, the court held the claims are directed to an improved method for classifying and sorting particles based on the specific steps set forth in the claims, thereby facilitating classification and sorting of each individual particle more accurately than any prior art method. Although the patent used mathematical equations to implement the improvement, the court found the claims were directed to an improvement to the method itself that so happened to use math. Because the court held that the claims are not directed to an abstract idea at Alice step one, it did not move on to step two.

The courts decision and its section 101 analysis offers several valuable lessons for litigants:

This pattern underscores the need for both patentees and challengers to make their case at Step One. Is it an improvement to an existing technology that so happens to use an abstract idea to implement that improvement, or are the claims directed to an improvement to the abstract idea itself? In XY, the invention improved a known flow cytometry process by applying a mathematical formula. While the court held that claimed improvement passed the Alice test, a claim directed to improving the mathematical formula by itself would likely not be eligible. XY makes clear that it is critical for patentees and challengers alike to define what the claims are directed to, knowing that step one is likely going to make or break the section 101 decision.

It is therefore critical for litigants to articulate, at Step One, what solutions existed in the prior art and why (or why not) the claims represent an improvement to those solutions. XY confirms the courts holding in Thales Visionix v United States that improving the accuracy of a prior art solution can be enough to make the claims a patentable improvement. Moreover, if a party can tie the claimed improvement to a physical process or product, all the better. The XY court found important the fact that the claimed method resulted in separation of physical particles, like the claimed improvement in Diamond v Diehr produced a perfectly-cured synthetic rubber product.

The Federal Circuits decision in XY confirms that claimed improvements to the prior art can be patent-eligible, even if the claims use an abstract idea such as a mathematical formula to execute the improvement. Litigants addressing section 101 challenges should focus on articulating what the claimed invention is, how it relates to the prior art, and how the claims compare to others that courts have already held to be eligible, or ineligible, under section 101.

Book your place at IPBC Connect today

Read the original post:
Three lessons from the Federal Circuit's recent 101 reversal in XY v Trans Ova Genetics - IAM

The Global Gene Therapy for Inherited Genetic Disorders Market report focuses on market size, status and forecast 2020-2027, along with this, report also focuses on market opportunities and treats, risk analysis, strategic and tactical decision-making and evaluating the market. The Gene Therapy for Inherited Genetic Disorders market report provides data and information on changing investment structure, technological advancements, market trends and developments, capacities, and detail information about the key players of the global Maarket_Keyword market. In addition to this, report also involves development of the Gene Therapy for Inherited Genetic Disorders market in major region across the world.

Key Players for Global Gene Therapy for Inherited Genetic Disorders Market:

The global Gene Therapy for Inherited Genetic Disorders market report profiles major key players of the market on the basis of business strategies, financial weaknesses and strengths and recent development.

BioMarin Pharmaceutical Inc.bluebird bio Inc.Novartis AGOrchard Therapeutics PlcSpark Therapeutics Inc.

Get Free Sample PDF (including full TOC, Tables and Figures) of Gene Therapy for Inherited Genetic Disorders Market @ https://www.apexmarketreports.com/Life-Science/global-gene-therapy-for-inherited-genetic-disorders-market-598591#sample

The Gene Therapy for Inherited Genetic Disorders market report also states demand and supply figures, revenue, production, import/export consumption as well as future strategies, sales volume, gross margins, technological developments, cost and growth rate. The Global Gene Therapy for Inherited Genetic Disorders Market report also delivers historical data from 2015 to 2020 and forecasted data from 2020 to 2027, along with SWOT analysis data of the market. This report includes information by types, by application, by region and by manufacturers or producers.

The recent outburst of the COVID-19 (Corona Virus Disease) has led the global Gene Therapy for Inherited Genetic Disorders market to render new solutions for combatting with the rising demand for protection against the virus. Due to this outbreak, remote patient monitoring, inpatient monitoring and interactive medicine is expected to gain grip at this time.

Global Gene Therapy for Inherited Genetic Disorders Market: Segmentation

Global Gene Therapy for Inherited Genetic Disorders Market Segmentation: By Types

Eye DisordersHematological DisordersCentral Nervous System DisordersMuscular DisordersOthers

Global Gene Therapy for Inherited Genetic Disorders Market segmentation: By Applications

HospitalClinicResearch InstituteOthers

Global Gene Therapy for Inherited Genetic Disorders Market Segmentation: By Region

Global Gene Therapy for Inherited Genetic Disorders market report categorized the information and data according to the major geographical regions like,

Place Inquiry for Buying or Customization of Report: https://www.apexmarketreports.com/Life-Science/global-gene-therapy-for-inherited-genetic-disorders-market-598591#inquiry

The Global Gene Therapy for Inherited Genetic Disorders market is displayed in 13 Chapters:

Chapter 1: Market Overview, Drivers, Restraints and OpportunitiesChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expensesChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13: Gene Therapy for Inherited Genetic Disorders Research Findings and Conclusion, Appendix, methodology and data source

Excerpt from:
Global Gene Therapy for Inherited Genetic Disorders Market 2020 Impact of COVID-19, Future Growth Analysis and Challenges | BioMarin Pharmaceutical...

Dr. Darryl Robinson, our board certified Medical Director and his expert team offer a full range of treatments for all ages, in a laid-back, friendly environment. Our process places an emphasis on learning about your goals and supporting you to make the best decision for you. We address everything from acne to weight loss to unwanted tattoos- and both men and women are welcomed with open arms.

We promise to provide the best customer service, vetted medical spa treatments, and equipment on the market. The Longevity team also offers the following to each client Complimentary Numbing with InjectablesComplimentary Pro-Nox pain control with Tattoo Removal, Halo, and Ultherapy Highly Trained Staff (in fact we require a minimum of 64 hours of continuing education per year per staff member)We don't aspire to make you a new person, but instead, to make you the fullest version of yourself-to help you feel great and to enhance what you've already got, without the pain and commitment of surgery.

Visit link:
Medical Spa, Body Sculpting and Non-Surgical ... - Longevity

Dr. Shigeaki Hinohara had an extraordinary life for many reasons. For starters, the Japanese physician and longevity expert lived until the age of 105.

When he died, in 2017, Hinohara was chairman emeritus of St. Luke's International University and honorary president of St. Luke's International Hospital, both in Tokyo.

Perhaps best known for his book, "Living Long, Living Good,"Hinohara offered advice that helped make Japan the world leader in longevity. Some were fairly intuitive points, while others were less obvious:

The average retirement age, at least in the U.S., has always hovered at around 65. And, in recent years, many have embraced the FIRE movement (Financial Independence, Retire Early).

ButHinohara viewed things differently. "There is no need to ever retire, but if one must, it should be a lot later than 65," he said in a 2009 interview with The Japan Times. "The current retirement age was set at 65 half a century ago, when the average life expectancy in Japan was 68 years and only 125 Japanese were over 100 years old."

Today, he explained, people are living a lot longer. The life expectancy for U.S. in 2020, for example, is78.93 years, a 0.08% increase from 2019. Therefore, we should be retiring much later in life, too.

Hinohara certainly practiced what he preached:Until a few months before his death, he continued to treat patients, kept an appointment book with space for five more years, and worked up to 18 hours a day.

Hinohara emphasized the importance of regular exercise. "I take two stairs at a time, to get my muscles moving," he said.

Additionally, Hinoharacarried his own packages and luggage, and gave 150 lectures a year, usually speaking for 60 to 90 minutes all done standing, he said, "to stay strong."

He also pointed out that people who live an extremely long life have a commonality: They aren't overweight. Indeed, obesity is widely considered one of the mostsignificant risk factorsfor increased morbidity and mortality.

Hinohara's diet was spartan: "For breakfast, I drink coffee, a glass of milk and some orange juice with a tablespoon of olive oil in it." (Studies have found that olive oil offers numerous health benefits, such as keeping your arteries clean and lowering heart disease risk.)

"Lunch ismilk and a few cookies, or nothing when I am too busy to eat," he continued. "I never get hungry because I focus on my work. Dinner is veggies, a bit of fish and rice, and, twice a week, 100 grams of lean meat."

According to Hinohara, not having a full schedule is a surefire way to age faster and die sooner. However, it's important to stay busy not just for the sakeof staying busy, but to be active in activities that help serve a purpose. (The logic is that one can be busy, yet still feel empty and idle on the inside.)

Hinohara found his purpose early on, after his mother's life was saved by the family's doctor.

Janit Kawaguchi, ajournalist who considered Hinohara a mentor,said, "He believed that life is all about contribution, so he had this incredible drive to help people, to wake up early in the morning and do something wonderful for other people. This is what was driving him and what kept him living."

"It's wonderful to live long," Hinohara said in the interview. "Until one is 60 years old, it is easy to work for one's family and to achieve one's goals. But in our later years, we should strive to contribute to society. Since the age of 65, I have worked as a volunteer. I still put in 18 hours seven days a week and love every minute of it."

While he clearly promoted exercise and nutrition as pathways to a longer and healthier life, Hinohara simultaneously maintained that we need not be obsessed with restricting our behaviors.

"We all remember how, as children, when we were having fun, we would forget to eat or sleep," he often said. "I believe we can keep that attitude as adults it is best not to tire the body with too many rules."

Richard Overton, one of America's oldest-surviving World War II veterans, would havemostlikely agreed.Right up until his death at age 112, the supercentenarian smoked cigars, drank whisky and ate fried food and ice cream on a daily basis.

Hinohara might not have approved of Overton's diet, but, to be fair, Overton did credit his longevity to maintaining a "stress-free life and keeping busy."

Hinohara cautioned against always taking the doctor's advice. When a test or surgery is recommended, he advised, "ask whether the doctor would suggest that his or her spouse or children go through such a procedure."

Hinohara insisted that science alone can't help people. It "lumps us all together, but illness is individual. Each person is unique, and diseases are connected to their hearts," he said. "To know the illness and help people, we need liberal and visual arts, not just medical ones."

In fact, Hinohara made sure that St. Luke's catered to the basic need of patients: "To have fun." The hospital provided music, animal therapy and art classes.

"Pain is mysterious, and having fun is the best way to forget it," he said. "If a child has a toothache, and you start playing a game together, he or she immediately forgets the pain."

According to The New York Times, toward the end of his life, Hinohara was unable to eat, but refused a feeding tube. He was discharged and died months later at home.

Instead of trying to fight death, Hinohara found peace in where he was through art. In fact, he credited his contentment and outlook toward life to a poem by Robert Browning, called"Abt Vogler" especially these lines:

There shall never be one lost good! What was, shall live as before;The evil is null, is nought, is silence implying sound;What was good shall be good, with, for evil, so much good more;On the earth the broken arcs; in the heaven a perfect round.

"My father used to read it to me," Hinohara recalled. "It encourages us to make big art, not small scribbles. It says to try to draw a circle so huge that there is no way we can finish it while we are alive. All we see is an arch; the rest is beyond our vision, but it is there in the distance."

Tom Popomaronisis a leadership researcher and vice president of innovation atMassive Alliance.His work has been featured in Forbes, Fast Company, Inc., and The Washington Post. In 2014, Tom was named one of the "40 Under 40" by the Baltimore Business Journal. Follow him on LinkedIn.

Don't miss:

See the original post here:
Japanese doctor who lived to 105his spartan diet, views on retirement, and other rare longevity tips - CNBC

The New York Jets managed to shore up some quality depth in the backfield behind LeVeon Bell by signing Frank Gore. It appears the 37-year-old continues to withstand the effects of Father Time.

Gore is entering his 16th year in the NFL heading into the 2020 NFL season. According to Ralph Vacchiano of Sports New York, head coach Adam Gase shared some high praise for how the Jets running back has looked in training camp:

He looks the same as he did 12 years ago. I cant explain it. When I watch him I flash back to 2008. He looks the same. I dont know how. It doesnt make sense.

Hes going to look like that when hes 60.

The Jets coach is one of the few coaches that has gotten to witness the different stages of Gores career play out firsthand. The two became well-acquainted during their stint with the San Francisco 49ers and they would eventually reunite with the Miami Dolphins heading into the 2018 campaign.

This relationship undoubtedly played a part in the mutual interest between Gore and the Jets this offseason. The veteran had even cited Gase as a major factor for his signing in free agency. Fortunately, it seems he has continued to display the type of skill set that has kept him in the NFL after all these years.

Gore is now slated to serve as a complementary option to Bell in the backfield. His experience should help serve as a stabilizing factor following an unprecedented offseason due to the coronavirus pandemic.

Read the original post:
Adam Gase amazed by Frank Gores incredible longevity in the NFL - ClutchPoints

Now more than ever, finding ways to live a healthy and happy life have become insurmountable. However, eating more of these two types of fat could be the answer to helping you boost your longevity.

New research suggests that as many as 700,000 deaths each year could be avoided if people ate more healthy fats.

Polyunsaturated fats are found in fish (as omega-3 polyunsaturated fats) and plants (mainly as omega-6 polyunsaturated fats in plant oils such as sunflower, safflower, seeds and nuts).

In a recently published analysis of international trends in health and dietary fat intakes, the dangers of not consuming enough healthy polyunsaturated fats was exposed.

From the worldwide database of heart deaths and dietary records it was calculated thateating too little healthy polyunsaturated fats increased the risk of heart disease by 8 percent.

READ MORE:Coronavirus: Health experts warn to stay away from this diet it will not protect you

Polyunsaturated fat is a type ofdietary fat and is one of the healthy fats, along with monounsaturated fat.

Polyunsaturated fat is different from saturated fat and trans-fat.

These unhealthy fats can increase your risk for heart disease and other health problems.

Therefore, consuming more polyunsaturated fat in your diet will significantly reduce your risk of heart disease and help to boost longevity.

DONT MISS

Polyunsaturated fats can help reduce bad cholesterol levels in your blood which can lower your risk of heart disease and stroke, said the American Heart Association.

The health site continued: They also provide nutrients to help develop and maintain your bodys cells.

Oils rich in polyunsaturated fats also contribute vitamin E to the diet, an antioxidant vitamin most are in more need of.

Oils rich in polyunsaturated fats also provide essential fats that your body needs but cant produce itself such as omega-6 and omega-3 fatty acids.

Replacing saturated fats with polyunsaturated fats as part of a healthy diet helps reduce risk for heart disease, health experts claim.

Saturated fat is the bad kind of fat that raises cholesterol levels in the blood, increasing risk for heart disease and stroke.

These types of fats are said to often be found in high-fat types of meat and dairy products, such as fatty beef, butter and cheese.

While eating these natural fats can help to boost longevity, eating fewer processed fats can also help increase lifespan by improving health.

Key culprits that contain more trans-fats and saturates, according to Dr Sarah Brewer and Juliette Kellow, include biscuits, cakes, takeaway foods, red meat and cheese.

Artificial trans-fats raise bad cholesterol and lower good cholesterol levels, they wrote. Avoid such fats, mostly hidden in processed foods.

Saturated fats tend to be solid at room temperature and increase levels of cholesterol in the blood.

Limit your intake of these foods.

The rest is here:
How to live longer: A type of fat to reduce your risk of heart disease and boost longevity - Express